- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07816666
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer (TREVI-OC-03)
7 september 2026 uppdaterad av: AstraZeneca
A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan With or Without Bevacizumab Versus Standard of Care as Second- or Third-Line Maintenance Treatment in Participants With Platinum-sensitive Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (TREVI-OC-03)
The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)
Studieöversikt
Status
Har inte rekryterat ännu
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Beräknad)
600
Fas
- Fas 3
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: AstraZeneca Clinical Study Information Center
- Telefonnummer: 1-877-240-9479
- E-post: information.center@astrazeneca.com
Studieorter
-
-
-
Auchenflower, Australien, 4066
- Research Site
-
Blacktown, Australien, 2148
- Research Site
-
Clayton, Australien, 3168
- Research Site
-
Liverpool, Australien, 2170
- Research Site
-
-
-
-
-
Porto Alegre, Brasilien, 90035903
- Research Site
-
São Caetano do Sul, Brasilien, 09541-270
- Research Site
-
São José do Rio Preto, Brasilien, 15090-000
- Research Site
-
São José dos Campos, Brasilien, 12210-030
- Research Site
-
São Paulo, Brasilien, 01327-001
- Research Site
-
Teresina, Brasilien, 64049-200
- Research Site
-
Vitória, Brasilien, 29043-260
- Research Site
-
-
-
-
Alaska
-
Anchorage, Alaska, Förenta staterna, 99508
- Research Site
-
-
Maryland
-
Columbia, Maryland, Förenta staterna, 21044
- Research Site
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48201
- Research Site
-
-
New York
-
Albany, New York, Förenta staterna, 12206
- Research Site
-
Bay Shore, New York, Förenta staterna, 11706
- Research Site
-
Greenlawn, New York, Förenta staterna, 11740
- Research Site
-
New Hyde Park, New York, Förenta staterna, 11042
- Research Site
-
New York, New York, Förenta staterna, 10029
- Research Site
-
Rego Park, New York, Förenta staterna, 11374
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Förenta staterna, 44195
- Research Site
-
Cleveland, Ohio, Förenta staterna, 44111
- Research Site
-
Columbus, Ohio, Förenta staterna, 43210
- Research Site
-
Mayfield Heights, Ohio, Förenta staterna, 44124
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19107
- Research Site
-
Willow Grove, Pennsylvania, Förenta staterna, 19090
- Research Site
-
-
West Virginia
-
Morgantown, West Virginia, Förenta staterna, 26506
- Research Site
-
-
-
-
-
Ahmedabad, Indien, 380060
- Research Site
-
Bangalore, Indien, 560004
- Research Site
-
Gurgaon, Indien, 122002
- Research Site
-
Kottayam, Indien, 686008
- Research Site
-
Madurai, Indien, 625107
- Research Site
-
Nashik, Indien, 422002
- Research Site
-
Nashik, Indien, 422 009
- Research Site
-
New Delhi, Indien, 11029
- Research Site
-
Vadodara, Indien, 391760
- Research Site
-
-
-
-
-
Fukuoka, Japan, 812-8582
- Research Site
-
Fukushima, Japan, 960-1295
- Research Site
-
Kobe, Japan, 650-0047
- Research Site
-
Kyoto, Japan, 612-8555
- Research Site
-
Kōtoku, Japan, 135-8550
- Research Site
-
Minatoku, Japan, 105-8471
- Research Site
-
Natori-shi, Japan, 981-1293
- Research Site
-
Sagamihara-shi, Japan, 252-0375
- Research Site
-
Shinjuku-ku, Japan, 160-0023
- Research Site
-
Suita-shi, Japan, 565-0871
- Research Site
-
Toyoake-shi, Japan, 470-1192
- Research Site
-
Yokohama, Japan, 236-0004
- Research Site
-
-
-
-
British Columbia
-
Abbotsford British Columbia, British Columbia, Kanada, V2S0C2
- Research Site
-
-
Quebec
-
Montreal, Quebec, Kanada, H3A 1A1
- Research Site
-
Montreal, Quebec, Kanada, H2X 0A9
- Research Site
-
-
-
-
-
Beijing, Kina, 100210
- Research Site
-
Guangdong Province, Kina, 510060
- Research Site
-
Guangzhou, Kina, 510060
- Research Site
-
Wuhan, Kina, 430030
- Research Site
-
-
-
-
-
Goyang-si, Sydkorea, 10408
- Research Site
-
Seoul, Sydkorea, 03080
- Research Site
-
Seoul, Sydkorea, 03722
- Research Site
-
Seoul, Sydkorea, 135-710
- Research Site
-
Seoul, Sydkorea, 5505
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 81362
- Research Site
-
Taichung, Taiwan, 40705
- Research Site
-
Taichung, Taiwan, 40447
- Research Site
-
Tainan, Taiwan, 70403
- Research Site
-
Taipei, Taiwan, 10449
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10210
- Research Site
-
Bangkok, Thailand, 10330
- Research Site
-
Bangkok, Thailand, 10700
- Research Site
-
Hat Yai, Thailand, 90110
- Research Site
-
Muang, Thailand, 50200
- Research Site
-
-
-
-
-
Bad Homburg, Tyskland, 61352
- Research Site
-
Bonn, Tyskland, 53127
- Research Site
-
Brandenburg, Tyskland, 14770
- Research Site
-
Gütersloh, Tyskland, 33332
- Research Site
-
Homburg, Tyskland, 66421
- Research Site
-
Kassel, Tyskland, 34125
- Research Site
-
Mainz, Tyskland, 55131
- Research Site
-
Mannheim, Tyskland, 68167
- Research Site
-
Wiesbaden, Tyskland, 65189
- Research Site
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Participants with confirmed histology of high-grade epithelial serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer.
- Provision of an archival FFPE tumour sample
- Participants who received at least one, and no more than 2 lines of prior systemic anticancer therapy.
- Participants with radiologically confirmed disease relapse ≥ 6 months after their last platinum chemotherapy infusion in the previous line of treatment
- Participants who received at least 6 cycles of PBC during the induction phase of their current line of treatment.
- Participants assigned to bevacizumab must have received a minimum of 3 cycles of bevacizumab with 3 cycles of PBC prior to randomisation.
- Participants with non-progressive disease upon completion of PBC in their current line of treatment.
- Participants with documented BRCA mutation 1/2 must have received prior PARP inhibitor (unless ineligible due to contraindications, precautions, or intolerance).
Exclusion Criteria:
- Participants with tumours of non-epithelial origin, borderline tumours, clear cell OC, mucinous OC, carcinosarcoma, or low-grade epithelial tumours.
- Participants with history of (non-infectious) ILD/pneumonitis that required steroids, or supplemental oxygen, or has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening
- Participants with non-healing wound, active ulcer, or bone fracture (not applicable if not receiving bevacizumab)
- Participants with evidence of active or ongoing bowel obstruction (not applicable if not receiving bevacizumab)
- Participants with prior exposure to any FRα-targeted therapy, including MIRV, or any TOP1i Antibody-drug Conjugate (ADC)
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Torvutatug samrotecan monotherapy or in combination with bevacizumab
Torvutatug samrotecan monotherapy intravenous (IV) or Torvutatug samrotecan IV with bevacizumab IV.
|
FRa targeting antibody drug conjugate Topoisomerase I inhibitor
Andra namn:
Monoclonal antibody inhibitor of Vascular Endothelial Growth Factor
|
|
Aktiv komparator: Observation or bevacizumab
Observation or bevacizumab IV.
|
Monoclonal antibody inhibitor of Vascular Endothelial Growth Factor
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression-Free Survival (PFS)
Tidsram: Up to approximately 5 years
|
PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by Blinded Independent Central Review, or death due to any cause.
|
Up to approximately 5 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall Survival (OS)
Tidsram: Up to approximately 5 years
|
OS is defined as time from randomisation until the date of death due to any cause.
|
Up to approximately 5 years
|
|
Second Progression-Free Survival (PFS2)
Tidsram: Up to approximately 5 years
|
PFS2 is defined as time from randomisation to the earliest of the progression event (following the initial investigator-assessed progression) after first subsequent therapy, or death.
|
Up to approximately 5 years
|
|
Time to First Subsequent Therapy (TFST)
Tidsram: Up to approximately 5 years
|
TFST is defined as time from randomisation until the start date of the first subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause.
|
Up to approximately 5 years
|
|
Time to Second Subsequent Therapy (TSST)
Tidsram: Up to approximately 5 years
|
TSST is defined as time from randomisation until the start date of the second subsequent anti-cancer therapy after discontinuation of randomised treatment, or death due to any cause.
|
Up to approximately 5 years
|
|
Health-related Quality of Life (HrQoL)
Tidsram: Up to approximately 5 years
|
Change from baseline and time to deterioration in global health status/quality of life (GHS/QoL), physical functioning (PF), and ovarian cancer symptoms (EORTC IL433).
|
Up to approximately 5 years
|
|
Number and percentage of participants with adverse events as graded by CTCAE v6 criteria
Tidsram: Up to approximately 5 years
|
Adverse Event Incidence
|
Up to approximately 5 years
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Beräknad)
29 september 2026
Primärt slutförande (Beräknad)
26 september 2028
Avslutad studie (Beräknad)
27 oktober 2031
Studieregistreringsdatum
Först inskickad
7 september 2026
Först inskickad som uppfyllde QC-kriterierna
7 september 2026
Första postat (Faktisk)
14 september 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
14 september 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
7 september 2026
Senast verifierad
1 september 2026
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Sjukdomar i det endokrina systemet
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Neoplasmer efter histologisk typ
- Genitala sjukdomar, kvinnor
- Neoplasmer i endokrina körtel
- Neoplasmer, körtel och epitel
- Ovariella sjukdomar
- Adnexala sjukdomar
- Genitala neoplasmer, hona
- Gonadal sjukdomar
- Carcinom
- Äggledarsjukdomar
- Karcinom, äggstocksepitel
- Ovariella neoplasmer
- Äggledarneoplasmer
- Aminosyror, peptider och proteiner
- Proteiner
- Antikroppar, monoklonal, humaniserad
- Antikroppar, monoklonal
- Antikroppar
- Immunglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Bevacizumab
Andra studie-ID-nummer
- D8992C00001
- 2026-526776-23-00 (Ctis)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
JA
IPD-planbeskrivning
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org.
All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Tidsram för IPD-delning
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Kriterier för IPD Sharing Access
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org.
Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Ja
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
produkt tillverkad i och exporterad från U.S.A.
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .